Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prognostic Significance of C-Reactive Protein to Albumin Ratio, Albumin to Fibrinogen Ratio, and Serum Ferritin Level in Newly Diagnosed De Novo Non-M3 Acute Myeloid Leukemia Patients

NCT07810829 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT07810829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07810829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prognostic Significance of C-Reactive Protein to Albumin Ratio, Albumin to Fibrinogen Ratio, and Serum Ferritin Level in Newly Diagnosed De Novo Non-M3 Acute Myeloid Leukemia Patients
Lead sponsor
Assiut University
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2028
Enrollment
208 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, de novo acute myeloid leukemia with multilineage dysplasia, non-m3 acute myeloid leukemia